Physician profile
Amina Saqib
NPI 1144578311
$3,184.17
in general payments reported to CMS, 2019-2025
30 companies · $664 in 2025
The $664 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,533 · 2020: $96.00 · 2021: $215 · 2022: $251 · 2023: $191 · 2024: $235 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,089.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,052.06 | 2019-2025 | Watchman Flx |
| Glaxosmithkline, LLC. | $662.59 | 2019-2025 | Nucala, Trelegy Ellipta |
| W. L. Gore & Associates, INC. | $191.10 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $172.67 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Mallinckrodt Hospital Products INC. | $127.60 | 2020-2025 | Acthar |
| Mylan Specialty L.P. | $111.51 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $84.56 | 2019-2024 | Dupixent |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Insmed, INC. | $70.36 | 2025 | Arikayce, Brinsupri |
| Amgen INC. | $65.15 | 2024-2025 | Tezspire |
| Viatris Specialty LLC | $62.49 | 2025 | Yupelri |
| Grifols USA, LLC | $50.92 | 2022-2025 | Prolastin-C Liquid |
| Axsome Therapeutics, INC. | $48.42 | 2022-2023 | Sunosi |
| Csl Behring | $44.21 | 2024-2025 | Hizentra |
| E.R. Squibb & Sons, L.L.C. | $44.14 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $35.80 | 2019 | |
| Genentech USA, INC. | $32.46 | 2022-2025 | Xolair |
| Inspire Medical Systems, INC. | $32.11 | 2025 | Inspire |
| Electromed, INC. | $28.72 | 2025 | Smartvest |
| Tanabe Pharma America, INC. | $26.88 | 2019 | |
| Sunovion Pharmaceuticals INC. | $21.87 | 2020 | |
| Lilly USA, LLC | $18.72 | 2024 | Jardiance, Zepbound |
| Verona Pharma, INC. | $18.04 | 2025 | Ohtuvayre |
| Tactile Systems Technology INC | $16.11 | 2020 | |
| Genzyme Corporation | $15.61 | 2023 | |
| Pfizer INC. | $15.45 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.83 | 2021 | |
| Pulmonx Corporation | $14.26 | 2025 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Mallinckrodt Enterprises LLC | $13.21 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amina Saqib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.